(-0.72%) 5 070.50 points
(-0.23%) 38 590 points
(-1.32%) 17 432 points
(0.21%) $82.98
(-0.67%) $1.642
(-0.35%) $2 330.30
(-0.55%) $27.20
(-0.45%) $911.70
(-0.20%) $0.933
(-0.19%) $10.96
(-0.21%) $0.801
(0.09%) $92.40
Quarter results today
(bmo 2024-04-25)
Expected move: +/- 6.05%
Live Chart Being Loaded With Signals
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis...
Stats | |
---|---|
Today's Volume | 4.65M |
Average Volume | 1.93M |
Market Cap | 57.50M |
EPS | £0 ( 2024-04-18 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -11.50 |
ATR14 | £0.122 (1.06%) |
Volume Correlation
Poolbeg Pharma PLC Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Poolbeg Pharma PLC Correlation - Currency/Commodity
Poolbeg Pharma PLC Financials
Annual | 2022 |
Revenue: | £0 |
Gross Profit: | £-26 000.00 (0.00 %) |
EPS: | £-0.00940 |
Q2 | 2023 |
Revenue: | £0 |
Gross Profit: | £-13 000.00 (0.00 %) |
EPS: | £-0.00360 |
Q4 | 2022 |
Revenue: | £0 |
Gross Profit: | £-13 000.00 (0.00 %) |
EPS: | £-0.00620 |
Q2 | 2022 |
Revenue: | £0 |
Gross Profit: | £-13 000.00 (0.00 %) |
EPS: | £-0.00320 |
Financial Reports:
No articles found.
Poolbeg Pharma PLC
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators